Mostrando 10 resultados de: 17
Filtros aplicados
Área temáticas
Enfermedades(15)
Farmacología y terapéutica(9)
Problemas sociales y servicios a grupos(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(17)
ODS 17: Alianzas para lograr los objetivos(17)
ODS 3: Salud y bienestar(17)
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusChronic vaccination with a therapeutic egf-based cancer vaccine: A review of patients receiving long lasting treatment
ArticleAbstract: Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despiPalabras claves:Cancer Vaccines, chronic vaccination, EGF, eGFRAutores:González G., Lage Davila A., Tania CrombetFuentes:scopusControl of advanced cancer: The road to chronicity
ArticleAbstract: Despite the recent trend toward a slight decrease in age-adjusted cancer mortality in some countriesPalabras claves:Advanced cancer, Biotechnology, Chronic treatment, Small moleculesAutores:Lage Davila A., Tania CrombetFuentes:scopusCIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer
ArticleAbstract: The results allowing the Cuban Regulatory Agency (CECMED) to grant the Sanitary Registration to thePalabras claves:cancer vaccine, CIMAvax-EGF, Fast-Track registration, NSCLC, Phase II-III clinical trialAutores:Arteaga N., Cuevas A., García Verdecia B., González G., Lage Davila A., Neninger Vinageras E., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusEvaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
ArticleAbstract: BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth FacPalabras claves:Autores:Alert J., Bach F., Ballesteros J., Catala M., de-Castro N., Domíngez R., Figueredo J., Griego M.G.o., Luaces P.L.o., Marinello J.J.u., Martell J.A.n., Quintanal N., Salva S., Selva J.C.é., Solomón M.T.e., Tania Crombet, Toledo C., Vaquer J.Fuentes:scopusPharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study
ArticleAbstract: Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti-epidermal growth factor recepPalabras claves:Autores:Albanell J., Bellosillo B., Campas C., Cedeño M., Corominas J.M., Corradino I., Cruz T., Gascon P., Gracias E., Iznaga N., Marsoni S., Osorio M., Rojo F., Rovira A., Serrano S., Sessa C., Tania Crombet, Villena N.Fuentes:scopusPhase i/ii clinical trial of the humanized anti-egf-r monoclonal antibody h-r3 labelled with <sup>99m</sup>tc in patients with tumour of epithelial origin
ArticleAbstract: To evaluate the biodistribution, internal radiation dosimetry and toxicity of the humanized MAb h-R3Palabras claves:biodistribution, Dosimetry, Humanized MAb, RadioimmunodiagnosisAutores:Aguilar V., Batista J.F., Coca M.A., Hernández A., Iznaga-Escobar N., Neninger Vinageras E., Perera A., Pérez M., Ramos M., Romero S., Sánchez E., Tania Crombet, Torres L.Fuentes:scopus